EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma

Dec 1, 2022, 00:00
10.1016/j.jval.2022.09.412
https://www.valueinhealthjournal.com/article/S1098-3015(22)02616-X/fulltext
Title : EE162 Cost-Effectiveness of Obinutuzumab Plus Bendamustine and Followed by Obinutuzumab Maintenance Therapy in Chinese Patients With Relapse and Refractory Follicular Lymphoma
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)02616-X&doi=10.1016/j.jval.2022.09.412
First page :
Section Title :
Open access? : No
Section Order : 12216
Categories :
Tags :
Regions :
ViH Article Tags :